title: Peripheral polyneuropathy during treatment with alpha-2 interferon.
authors.forename: L
authors.initials: L
authors.lastname: Cudillo
authors.forename: M
authors.initials: M
authors.lastname: Cantonetti
authors.forename: A
authors.initials: A
authors.lastname: Venditti
authors.forename: R
authors.initials: R
authors.lastname: Lentini
authors.forename: P M
authors.initials: PM
authors.lastname: Rossini
authors.forename: M
authors.initials: M
authors.lastname: Caramia
authors.forename: M
authors.initials: M
authors.lastname: Masi
authors.forename: G
authors.initials: G
authors.lastname: Papa
mesh_terms: D006801:Humans; D007155:Immunologic Factors / Q000009:adverse effects* / Q000627:therapeutic use; D007370:Interferon Type I / Q000009:adverse effects* / Q000627:therapeutic use; D007866:Leg; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000150:complications / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D009046:Motor Neurons / Q000187:drug effects; D009133:Muscular Atrophy / Q000139:chemically induced; D010523:Peripheral Nervous System Diseases / Q000139:chemically induced*; D011994:Recombinant Proteins
chemical_list: D007155:Immunologic Factors; D007370:Interferon Type I; D011994:Recombinant Proteins